Amgen (NASDAQ:AMGN) today announced that it will report its second quarter 2025 financial results on Tuesday, August 5, 2025, after the close of the U.S. financial markets. The announcement will be ...

Kissei Pharmaceutical is paying Viridian Therapeutics $70 million upfront for Japanese rights to a pair of thyroid eye ...

Amgen Inc. (NASDAQ:AMGN) is one of the most undervalued blue chip stocks to buy according to hedge funds. On July 21, UBS ...

We expect Amgen AMGN to beat expectations when it reports second-quarter 2025 results on Aug. 5 after market close. In the ...

With a $5 billion investment, the 3,000-employee campus leads biomanufacturing innovation while embracing AI, education and ...

Amgen (AMGN) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

On July 24, 2025, the PTO Acting Director Coke Morgan Stewart discretionarily denied Amgen’s IPR2025-00601 and IPR2025-00602 challenging ...

The results are very encouraging news for Amgen and Repatha, which is in a head-to-head marketing battle with Sanofi and Regeneron’s Praluent to be the dominant PCSK9 inhibitor.

Topline The Federal Trade Commission announced Friday it had reached a settlement with Amgen Inc. over the biopharmaceutical firm’s $27.8 billion acquisition of Horizon Therapeutics, after the ...

Long Trade IdeaEnter your long position between 297.78 (yesterday's intra-day low) and 304.07 (yesterday's intra-day high).Market Index Analys ...

Biotechnology company, Amgen, has announced that it has entered into a definitive agreement to acquire deCODE Genetics, a global leader in human genetics, for US $415 million. The all-cash ...

Amgen won FDA approval for a cancer immunotherapy made from a genetically modified form of the cold sore virus. Here's how the drug could contribute to the rapidly growing field of immuno-oncology.